NEW YORK – Gritstone Oncology on Monday announced that it had begun dosing patients in the Phase II expansion cohorts of clinical trials evaluating its neoantigen-based immunotherapies GRANITE and SLATE.
NEW YORK – Gritstone Oncology on Monday announced that it had begun dosing patients in the Phase II expansion cohorts of clinical trials evaluating its neoantigen-based immunotherapies GRANITE and SLATE.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.